Irofulven | m-entrepreneurship.com

Product Name :
Irofulven

Search keywords :
(-)-Irofulven

drugId :
null

Target Vo:
RNA polymerase II

Target Vo Short Name :
RNA polymerase II

Moa_Name:
Alkylating agents

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Oncology Venture A/S

Active Company_Name :
Allarity Therapeutics A/S

Active Indication_Name:
Prostatic Neoplasms, Castration-Resistant

In Active Indication_Name:
Leukemia

Termination Status :

China Termination Status :

Highest Status:
Phase 2 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Belimumab supplier
CD8 Antibody Purity & Documentation
CHRNA9 Antibody: CHRNA9 Antibody is an unconjugated, approximately 55 kDa, rabbit-derived, anti-CHRNA9 polyclonal antibody. CHRNA9 Antibody can be used for: WB, IHC-P expriments in human, rat background without labeling.

Author: Betaine hydrochloride

Related Posts